Strata Critical Medical Management Commentary: Clinical Acquisitions, Growth Drive Q3 2026 Revenue Up 50.3%

• Strata Critical Medical management's commentary attributed third-quarter 2026 revenue growth of 50.3% to $74.1 million primarily to Clinical acquisitions and growth.
• Adjusted EBITDA rose to $9.6 million from $4.2 million a year earlier, supported by Clinical growth, improved Logistics margins and overhead control.
• Logistics revenue fell 3.5% year over year as shorter industry trip distances and reduced flying by a nonexclusive customer weighed on performance.
• Management attributed the $7.6 million net loss from continuing operations entirely to noncash, transaction-related charges, including intangible asset amortization.
• Free cash flow reached a record $8.6 million, benefiting from low aircraft maintenance spending that limited capital expenditures to $0.8 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Strata Critical Medical Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.